Thiotepa and Polivy drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Thiotepa (thiotepa) and Polivy (polatuzumab vedotin-piiq). Common drug interactions include drug ineffective among females and disease progression among males.

The phase IV clinical study analyzes what interactions people have when they take Thiotepa and Polivy. It is created by eHealthMe based on reports of 19 people who take the same drugs from the FDA, and is updated regularly.

What is Thiotepa?

Thiotepa has active ingredients of thiotepa. eHealthMe is studying from 8,097 Thiotepa users. Check the latest studies of Thiotepa.

What is Polivy?

Polivy has active ingredients of polatuzumab vedotin-piiq. eHealthMe is studying from 2,455 Polivy users. Check the latest studies of Polivy.



On Aug, 02, 2026

19 people who take Thiotepa and Polivy together, and have interactions are studied.

Thiotepa and Polivy drug interactions.

What are the common drug interactions of Thiotepa and Polivy, by gender? *:

female:

  1. Drug ineffective
  2. Blood lactate dehydrogenase increased
  3. Disease progression

male:

  1. Disease progression
  2. Nervous system disorder (a general class of medical conditions affecting the nervous system)
  3. Renal failure (kidney dysfunction)
  4. Thrombotic microangiopathy (a pathology that results in thrombosis in capillaries and arterioles, due to an endothelial injury)
  5. Cytomegalovirus infection
  6. Lymphoma (cancer that begins in immune system cells)
  7. Malignant neoplasm progression (cancer tumour came back)
  8. Neoplasm progression (growth of tumour)

What are the common drug interactions of Thiotepa and Polivy, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Disease progression
  2. Nervous system disorder (a general class of medical conditions affecting the nervous system)
  3. Renal failure (kidney dysfunction)
  4. Thrombotic microangiopathy (a pathology that results in thrombosis in capillaries and arterioles, due to an endothelial injury)
  5. Blood lactate dehydrogenase increased
  6. Cytomegalovirus infection
  7. Drug ineffective
  8. Lymphoma (cancer that begins in immune system cells)
  9. Malignant neoplasm progression (cancer tumour came back)
  10. Neoplasm progression (growth of tumour)

50-59:

n/a

60+:

n/a

What are the existing conditions these people have? *

  1. Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 19 people, 100.00%
  2. Diffuse Large B-Cell Lymphoma Refractory (cancer of b cells, a type of white blood cell-relapsed): 2 people, 10.53%
  3. Non-Hodgkin's Lymphoma Stage Iv (malignant (cancer) cells form in the lymph system- stageiv): 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Thiotepa and Polivy?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Thiotepa and Polivy:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Thiotepa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Polivy:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Thiotepa and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Polivy and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on thiotepa and polatuzumab vedotin-piiq (the active ingredients of Thiotepa and Polivy, respectively), and Thiotepa and Polivy (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: